Diamyd Medical meets study goal with diabetes vaccine

A vaccine candidate for diabetes, Diamyd, has met its primary endpoint in a phase II study, with 14 participants remaining insulin-independent 12 months after first injection.

Photo: Diamyd Medical / PR

A clinical phase II trial of diabetes vaccine candidate Diamyd has shown positive topline results, the vaccine’s developer Diamyd Medical reports in a press release.

The candidate specifically targets patients with the autoimmune form of diabetes known as LADA, or Latent Autoimmune Diabetes in Adults. According to the company, around 10% of adults diagnosed with type 2 diabetes have the autoimmune version, which has also been labelled as type 1.5 diabetes by some.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs